DK1042001T3 - Anvendelse af mikropartikler kombineret med submikron-(olie-i-vand)-emulsioner - Google Patents
Anvendelse af mikropartikler kombineret med submikron-(olie-i-vand)-emulsionerInfo
- Publication number
- DK1042001T3 DK1042001T3 DK98904739T DK98904739T DK1042001T3 DK 1042001 T3 DK1042001 T3 DK 1042001T3 DK 98904739 T DK98904739 T DK 98904739T DK 98904739 T DK98904739 T DK 98904739T DK 1042001 T3 DK1042001 T3 DK 1042001T3
- Authority
- DK
- Denmark
- Prior art keywords
- water
- submicron
- oil
- emulsions
- microparticles combined
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/918—Immunological
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Colloid Chemistry (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6972497P | 1997-12-16 | 1997-12-16 | |
PCT/US1998/001656 WO1999030737A1 (en) | 1997-12-16 | 1998-01-29 | Use of microparticles combined with submicron oil-in-water emulsions |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1042001T3 true DK1042001T3 (da) | 2002-07-08 |
Family
ID=22090819
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK98904739T DK1042001T3 (da) | 1997-12-16 | 1998-01-29 | Anvendelse af mikropartikler kombineret med submikron-(olie-i-vand)-emulsioner |
Country Status (11)
Country | Link |
---|---|
US (4) | US6086901A (da) |
EP (1) | EP1042001B1 (da) |
JP (3) | JP4918188B2 (da) |
AT (1) | ATE215385T1 (da) |
AU (1) | AU6253898A (da) |
CA (1) | CA2314934C (da) |
DE (1) | DE69804671T2 (da) |
DK (1) | DK1042001T3 (da) |
ES (1) | ES2175668T3 (da) |
PT (1) | PT1042001E (da) |
WO (1) | WO1999030737A1 (da) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0832638B2 (ja) * | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
DE59409668D1 (de) | 1993-12-23 | 2001-04-05 | Bruno Gander | Mit Antigen beladene Mikropartikel und pharmazeutische Zubereitungen, die diese Mikropartikel enthalten. |
EP1860192A1 (en) * | 1996-09-17 | 2007-11-28 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating intracellular diseases |
US20040202680A1 (en) * | 1997-01-30 | 2004-10-14 | O'hagan Derek | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
DE69812941T2 (de) * | 1997-01-30 | 2004-02-05 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr |
US6884435B1 (en) | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
US7393630B2 (en) * | 1997-12-16 | 2008-07-01 | Novartis Vaccines And Diagnostics, Inc. | Use of microparticles combined with submicron oil-in-water emulsions |
CA2314934C (en) * | 1997-12-16 | 2006-08-29 | Chiron Corporation | Use of microparticles combined with submicron oil-in-water emulsions |
ES2228454T3 (es) * | 1999-02-26 | 2005-04-16 | Chiron S.R.L. | Mejora de la actividad bacteriana de antigenos de neisseria con oligonucleotidos que contienen motivos cg. |
CA2689696C (en) * | 1999-02-26 | 2013-08-06 | Novartis Vaccines And Diagnostics, Inc. | Microemulsions with adsorbed macromolecules and microparticles |
ES2337017T3 (es) * | 1999-10-13 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Procedimiento para obtener respuestas inmunitarias celulares de proteinas. |
DE60026571T2 (de) * | 1999-11-19 | 2006-12-14 | MGI Pharma Biologics, Inc., Lexington | Durchflussverfahren zur herstellung von mikropartikeln |
US7329408B2 (en) * | 1999-12-01 | 2008-02-12 | Novartis Vaccines And Diagnostics, Inc. | Eliciting HCV-specific antibodies |
US7129222B2 (en) * | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
US20040022814A1 (en) * | 2000-06-15 | 2004-02-05 | O'hagan Derek | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
US20030138769A1 (en) * | 2000-08-16 | 2003-07-24 | Birkett Ashley J. | Immunogenic HBc chimer particles having enhanced stability |
US6753015B2 (en) | 2000-09-28 | 2004-06-22 | Chiron Corporation | Microparticle compositions and methods for the manufacture thereof |
SG137691A1 (en) * | 2000-09-28 | 2007-12-28 | Chiron Corp | Microparticles for delivery of the heterologous nucleic acids |
CA2439111A1 (en) * | 2001-04-05 | 2002-10-17 | Chiron Corporation | Mucosal boosting following parenteral priming |
US8481043B2 (en) * | 2001-06-22 | 2013-07-09 | Cpex Pharmaceuticals, Inc. | Nasal immunization |
CZ20033515A3 (cs) * | 2001-06-29 | 2005-01-12 | Chiron Corporation | Kompozice vakcíny HCV E1E2 |
US20030185858A1 (en) * | 2001-08-15 | 2003-10-02 | Birkett Ashley J. | Immunogenic HBc chimer particles stabilized with an N-terminal cysteine |
US20030175863A1 (en) * | 2001-08-15 | 2003-09-18 | Birkett Ashley J. | Influenza immunogen and vaccine |
US7361352B2 (en) * | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
CN1620253A (zh) * | 2001-12-27 | 2005-05-25 | 创世纪集团公司 | 海豹油基脂质乳液及其用途 |
ES2339762T3 (es) * | 2002-01-14 | 2010-05-25 | Novartis Vaccines And Diagnostics, Inc. | Vacuna contra el vih y procedimiento de uso. |
US7351413B2 (en) * | 2002-02-21 | 2008-04-01 | Lorantis, Limited | Stabilized HBc chimer particles as immunogens for chronic hepatitis |
US6861410B1 (en) | 2002-03-21 | 2005-03-01 | Chiron Corporation | Immunological adjuvant compositions |
WO2003082316A1 (en) * | 2002-03-29 | 2003-10-09 | The Regents Of The University Of California | Microgel particles for the delivery of bioactive materials |
WO2004004654A2 (en) * | 2002-07-03 | 2004-01-15 | Cambridge Scientific, Inc. | Vaccines to induce mucosal immunity |
AU2003254792A1 (en) * | 2002-08-02 | 2004-02-23 | Sumitomo Pharmaceuticals Company, Limited | Bacterial cell wall skeleton component preparaion |
NZ538628A (en) * | 2002-08-12 | 2008-06-30 | Dynavax Tech Corp | Immunomodulatory compositions, methods of making, and methods of use thereof |
CA2823937A1 (en) * | 2002-10-07 | 2004-04-22 | Novartis Vaccines And Diagnostics, Inc. | Hiv vaccine formulations |
AU2003286512A1 (en) * | 2002-10-18 | 2004-05-04 | Charles N. Ellis | Method for rating severity of psoriasis |
WO2004060396A2 (en) * | 2002-12-27 | 2004-07-22 | Chiron Corporation | Immunogenic compositions containing phospholpid |
US20050191358A1 (en) * | 2003-01-14 | 2005-09-01 | Derek O' Hagan | Microparticles with adsorbed polynucleotide-containing species |
DK1613346T3 (da) * | 2003-04-04 | 2013-01-07 | Pah Usa 15 Llc | Mikrofluidiske olie-i-vand-emulsioner og vaccinesammensætninger |
WO2004091491A2 (en) * | 2003-04-10 | 2004-10-28 | Transform Pharmaceuticals, Inc. | Profiling conformational variants, antibody compositions and methods of using the same |
US20070207211A1 (en) * | 2003-04-10 | 2007-09-06 | Pr Pharmaceuticals, Inc. | Emulsion-based microparticles and methods for the production thereof |
AU2004253853B2 (en) * | 2003-04-10 | 2010-04-01 | Evonik Corporation | A method for the production of emulsion-based micro particles |
EP1622566A4 (en) * | 2003-04-25 | 2008-06-25 | Novartis Vaccines & Diagnostic | COMPOSITIONS WITH CATIONIC MICROTEILS AND HCV E1E2 DNA AND METHOD OF APPLICATION THEREOF |
ES2328697T5 (es) | 2003-06-02 | 2017-07-25 | Novartis Vaccines And Diagnostics, Inc. | Composiciones inmunogénicas basadas en micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido |
US7208395B2 (en) * | 2003-06-26 | 2007-04-24 | Semiconductor Energy Laboratory Co., Ltd. | Laser irradiation apparatus, laser irradiation method, and method for manufacturing semiconductor device |
WO2005013896A2 (en) * | 2003-07-09 | 2005-02-17 | Vaxdesign Corporation | Programmed immune responses using a vaccination node |
AU2004259208B2 (en) * | 2003-07-15 | 2011-04-28 | Evonik Corporation | Method for the preparation of controlled release formulations |
EP2444069B1 (en) * | 2003-07-23 | 2019-06-05 | Evonik Corporation | Controlled release compositions |
WO2005102369A1 (ja) * | 2004-04-22 | 2005-11-03 | Dainippon Sumitomo Pharma Co., Ltd. | 細菌細胞壁骨格成分を含有する製剤 |
FR2873386B1 (fr) | 2004-07-22 | 2011-01-14 | Agence Francaise De Securite Sanitaire Des Aliments Afssa | Composition vaccinale contre le rhodococcus equi |
WO2007013893A2 (en) * | 2004-11-15 | 2007-02-01 | Novartis Vaccines And Diagnostics Inc. | Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant |
MX2009004866A (es) | 2006-11-03 | 2009-05-19 | Schering Plough Ltd | Vacuna para enfermedad de lyme canina. |
CL2008001806A1 (es) | 2007-06-20 | 2008-09-05 | Wyeth Corp | Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion. |
BRPI0815008B8 (pt) * | 2007-08-02 | 2021-05-25 | Biondvax Pharmaceuticals Ltd | vacinas multiméricas com múltiplos epítopos contra influenza |
EP2197497B1 (en) | 2007-09-27 | 2016-06-01 | ImmunoVaccine Technologies Inc. | Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo |
US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
CA2744739A1 (en) | 2007-12-03 | 2009-06-11 | President And Fellows Of Harvard College | Chlamydia antigens |
US8815253B2 (en) * | 2007-12-07 | 2014-08-26 | Novartis Ag | Compositions for inducing immune responses |
WO2009111588A1 (en) * | 2008-03-04 | 2009-09-11 | Liquidia Technologies, Inc. | Immunomodulator particles and methods of treating |
CN102056622B (zh) * | 2008-06-05 | 2016-04-06 | 免疫疫苗技术有限公司 | 包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物 |
US20110236489A1 (en) * | 2008-09-18 | 2011-09-29 | Novartis Ag | Vaccine adjuvant combinations |
KR20110091560A (ko) | 2008-12-03 | 2011-08-11 | 프로테아 벡신 테크놀로지스 엘티디. | 글루타밀 tRNA 합성효소(GtS) 단편들 |
WO2011067758A2 (en) | 2009-12-02 | 2011-06-09 | Protea Vaccine Technologies Ltd. | Immunogenic fragments and multimers from streptococcus pneumoniae proteins |
AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
US20110293690A1 (en) * | 2010-05-27 | 2011-12-01 | Tyco Healthcare Group Lp | Biodegradable Polymer Encapsulated Microsphere Particulate Film and Method of Making Thereof |
JP6025721B2 (ja) | 2010-07-06 | 2016-11-16 | ノバルティス アーゲー | カチオン性水中油型エマルジョン |
AU2011360572B2 (en) | 2011-02-22 | 2017-03-02 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
LT2691530T (lt) | 2011-06-10 | 2018-08-10 | Oregon Health & Science University | Cmv glikoproteinai ir rekombinantiniai vektoriai |
US20130004640A1 (en) * | 2011-07-01 | 2013-01-03 | Pepsico, Inc. | Complex coacervates, methods and food products |
RU2606846C2 (ru) | 2011-07-06 | 2017-01-10 | Новартис Аг | Эмульсии типа "масло в воде", которые содержат нуклеиновые кислоты |
ES2702318T3 (es) | 2011-07-06 | 2019-02-28 | Glaxosmithkline Biologicals Sa | Emulsiones catiónicas de aceite en agua |
US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
BR112014007927B1 (pt) | 2011-10-06 | 2021-04-13 | Immunovaccine Technologies Inc | Composições de lipossoma compreendendo um adjuvante e usos das referidas composições e usos das referidas composições |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
EP2833900B1 (en) | 2012-04-01 | 2018-09-19 | Technion Research & Development Foundation Limited | Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies |
EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
CA2944768C (en) | 2014-04-03 | 2022-08-30 | Biondvax Pharmaceuticals Ltd. | Compositions of multimeric-multiepitope influenza polypeptides and their production |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5075109A (en) * | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
JPH0832638B2 (ja) * | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
CA2086094C (en) * | 1990-06-29 | 2000-05-30 | Gail L. Barchfeld | Vaccine compositions containing liposomes |
US5928865A (en) * | 1992-03-02 | 1999-07-27 | Chiron S.P.A. | Compositions comprising isolated Helicobacter pylori CagI polynucleotides and method of preparation thereof |
CA2172509C (en) * | 1993-10-22 | 2010-08-24 | Jeffrey L. Cleland | Methods and compositions for microencapsulation of antigens for use as vaccines |
US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
US5629167A (en) * | 1994-04-19 | 1997-05-13 | Biocine S.P.A. | Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay |
AU2656295A (en) * | 1994-06-02 | 1996-01-04 | Chiron Corporation | Nucleic acid immunization using a virus-based infection/transfection system |
GB9412273D0 (en) * | 1994-06-18 | 1994-08-10 | Univ Nottingham | Administration means |
SK165197A3 (en) * | 1995-06-07 | 1999-01-11 | Astra Ab | Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics |
GB9514285D0 (en) * | 1995-07-13 | 1995-09-13 | Univ Nottingham | Polymeric lamellar substrate particles for drug delivery |
GB9518864D0 (en) * | 1995-09-14 | 1995-11-15 | Cambridge Res & Innovation | Oligonucleotides and their uses |
GB9603314D0 (en) * | 1996-02-16 | 1996-04-17 | Biocine Spa | Immunogenic detoxified mutant toxins |
US5783567A (en) * | 1997-01-22 | 1998-07-21 | Pangaea Pharmaceuticals, Inc. | Microparticles for delivery of nucleic acid |
CA2314934C (en) * | 1997-12-16 | 2006-08-29 | Chiron Corporation | Use of microparticles combined with submicron oil-in-water emulsions |
-
1998
- 1998-01-29 CA CA002314934A patent/CA2314934C/en not_active Expired - Fee Related
- 1998-01-29 DK DK98904739T patent/DK1042001T3/da active
- 1998-01-29 WO PCT/US1998/001656 patent/WO1999030737A1/en active IP Right Grant
- 1998-01-29 ES ES98904739T patent/ES2175668T3/es not_active Expired - Lifetime
- 1998-01-29 EP EP98904739A patent/EP1042001B1/en not_active Expired - Lifetime
- 1998-01-29 US US09/015,736 patent/US6086901A/en not_active Expired - Lifetime
- 1998-01-29 JP JP2000538716A patent/JP4918188B2/ja not_active Expired - Fee Related
- 1998-01-29 AU AU62538/98A patent/AU6253898A/en not_active Abandoned
- 1998-01-29 PT PT98904739T patent/PT1042001E/pt unknown
- 1998-01-29 DE DE69804671T patent/DE69804671T2/de not_active Expired - Lifetime
- 1998-01-29 AT AT98904739T patent/ATE215385T1/de active
-
2000
- 2000-05-02 US US09/564,416 patent/US6306405B1/en not_active Expired - Lifetime
-
2001
- 2001-08-20 US US09/935,466 patent/US6458370B1/en not_active Expired - Lifetime
-
2002
- 2002-08-02 US US10/211,025 patent/US6855492B2/en not_active Expired - Lifetime
-
2007
- 2007-11-09 JP JP2007292637A patent/JP2008050374A/ja not_active Withdrawn
-
2011
- 2011-11-16 JP JP2011250804A patent/JP2012036223A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO1999030737A1 (en) | 1999-06-24 |
PT1042001E (pt) | 2002-09-30 |
JP2002508334A (ja) | 2002-03-19 |
JP2012036223A (ja) | 2012-02-23 |
DE69804671D1 (de) | 2002-05-16 |
US6086901A (en) | 2000-07-11 |
CA2314934A1 (en) | 1999-06-24 |
DE69804671T2 (de) | 2002-11-21 |
EP1042001B1 (en) | 2002-04-03 |
JP2008050374A (ja) | 2008-03-06 |
AU6253898A (en) | 1999-07-05 |
US20020025329A1 (en) | 2002-02-28 |
US20030082213A1 (en) | 2003-05-01 |
ES2175668T3 (es) | 2002-11-16 |
CA2314934C (en) | 2006-08-29 |
ATE215385T1 (de) | 2002-04-15 |
US6855492B2 (en) | 2005-02-15 |
EP1042001A1 (en) | 2000-10-11 |
US6458370B1 (en) | 2002-10-01 |
JP4918188B2 (ja) | 2012-04-18 |
US6306405B1 (en) | 2001-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1042001T3 (da) | Anvendelse af mikropartikler kombineret med submikron-(olie-i-vand)-emulsioner | |
BR0000126A (pt) | Adjuvantes para uso em vacinas | |
DK0724432T3 (da) | Fremgangsmåder og præparater til mikroindkapsling af antigener til brug som vacciner | |
ATE183198T1 (de) | Immunogens gegen gonadotropin releasing hormone | |
WO2005037190A3 (en) | Multiplex vaccines | |
DE69734006D1 (de) | Verfahren zur erleichterung von schmerzen durch eine kombination von tramadol und einen nmda-antagonist | |
DE60125797D1 (de) | Impfstoffzusammesetzung | |
ATE290879T1 (de) | Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung | |
DK0942740T3 (da) | Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme | |
ATE196314T1 (de) | Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit | |
NO983999D0 (no) | Peptidimmunogener for vaksinasjon mot og behandling av allergi | |
SE9600648D0 (sv) | Receptorbimdande enhet | |
FI925835A0 (fi) | Vacciner innehaollande liposomer | |
BR9612619A (pt) | Método e composição para reconformar antígenos multiepitópicos para iniciar uma resposta imunológica | |
ES2196150T3 (es) | Induccion de tolerancia inmunologica por el uso de anticuerpos anti-cd4 que no inducen deplecion. | |
EE9900146A (et) | Lahustuvad lümfotoksiin-ß retseptorid, lümfotoksiini retseptori vastased antikehad ja lümfotoksiini ligandi vastased antikehad terapeutiliste agensitena immunoloogiliste haiguste raviks | |
ATE118351T1 (de) | Wirkung von hormonen. | |
ES2177535T3 (es) | Vacunas contra protozoos intestinales. | |
DE69836976D1 (de) | Neospora impstoff | |
ATE245163T1 (de) | Impfstoff gegen metastasierenden kolorektalkrebs. | |
DE69928523D1 (de) | Verotoxin b untereinheit zur immunisierunug | |
NO20014772L (no) | Fremgangsmåter for forhindring eller attenuering av patoangiogene tilstander | |
FR2846237B1 (fr) | Composition sous forme d'emulsion huile-dans-eau et ses utilisations notamment cosmetiques | |
DE60334550D1 (de) | Igg2 antikörper gegen exkretion sekretion antigenen von leishmania promastigoten oder amastigoten |